1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

US FDA Advisors Want Iterum’s Antibiotic Indication Narrowed

 
• By Sarah Karlin-Smith

The agency’s Antimicrobial Drugs Advisory Committee suggested a more limited indication for Interum’s antibiotic for uncomplicated urinary tract infections than the sponsor proposed, though it wasn’t necessarily clear committee members favored approval.

Sulopenem advisory committee meeting
The FDA held the first fully in-person advisory committee since the emergence of COVID-19 on 9 September at its Maryland headquarters. • Source: Sarah Karlin-Smith

Iterum Therapeutics plc’s oral antibiotic sulopenem etzadroxil/probenecid for uncomplicated urinary tract infections could be headed for US Food and Drug Administration approval, albeit with a much narrower label than proposed before the 9 September Antimicrobial Drugs Advisory Committee meeting.

Key Takeaways

  • Though no formal vote was taken, the FDA’s Antimicrobial Drugs Advisory Committee did not appear to support Iterum's uUTI antibiotic approval with the proposed labeling.

Iterum is seeking an indication in adult women for the treatment of uncomplicated urinary tract infection (uUTI) caused by designated...

Welcome to Pink Sheet

Create an account to read this article

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers

US FDA’s Second Half 2025 User Fee Goals Swing Toward Respiratory Disease

 
• By Bridget Silverman

The 43 novel agents with user fee goal dates in the remainder of 2025 have fewer oncologics and infectious disease drugs than the first half of the year.

Slowdown: US FDA’s 2025 Novel Approvals Are On Below-Average Pace

 
• By Bridget Silverman

US FDA's 25 novel approvals in 2025 fell short of the agency's five-year average count, driven by a drop in drugs center approvals; 45 user fee goals remain in second half of year.

Global Pharma Guidance Tracker - June 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.